

1 State of Alaska
2 Department of Commerce, Community and Economic Development
3 Division of Corporations, Business and Professional Licensing
4

5 Alaska Board of Pharmacy
6

7 DRAFT MINUTES OF THE MEETING
8 February 28 – March 2, 2018
9

10 By authority of AS 08.01.070(2), and in compliance with the provisions of AS 44.62,
11 Article 6, a scheduled meeting of the Board of Pharmacy was held via WebEx and at
12 the State Office Building, Conference Room A in Juneau, Alaska on February 28 –
13 March 2, 2018.
14

15
16
17 Agenda Item 1 Call to Order/Roll Call Time: 9:43 a.m.
18

19 The February 28, 2018 meeting day was called to order by Chair, Leif Holm at 9:43 a.m.
20

21 Board members present, constituting a quorum:
22

23 Leif Holm, PharmD #PHAP1606 – *Chair*
24 Richard Holt, PharmD #PHAP2008, MBA – *Vice Chair*
25 Phil Sanders, RPh #PHAP776
26 James Henderson, RPh #PHAP1683
27 Anne Gruening, Public Member
28 Lana Bell, RPh #PHAP893
29 Tammy Lindemuth, Public Member
30 Sharon Long, Public Member (effective 03/01/2018; via phone)
31

32 Division staff present:
33

34 Donna Bellino, Occupational Licensing Examiner
35 Laura Carrillo, Records & Licensing Supervisor
36 Melissa Dumas, Administrative Officer
37 Marilyn Zimmerman, Paralegal
38 Brian Howes, Investigator
39

40 Public members present:
41

42 Greg Estep, #PHAP2259, Walgreens (via phone)

86 Chair Holm commented on the 2016 open cases, inquiring whether there were specific hang-ups
87 delaying resolution of these outstanding matters. Mr. Howes indicated that some of the matters
88 would be resolved and that some may carry additional charges. Chair Holm commented that the
89 drug diversion matter should be having more momentum and Rich Holt added that the
90 unresolved two-year unprofessional conduct case should be resolved. Speaking on this delay,
91 Chair Holm reiterated legislative audit's previous findings that investigative matters were not being
92 resolved in a timely manner. Chair Holm acknowledged the work load Mr. Howes has with
93 investigations relating to pharmacy as well as to the Prescription Drug Monitoring Program
94 (PDMP), but encouraged close follow-up with these cases to be resolved more timely.

95

96 **Agenda Item 6 Public Comment Time: 9:53 a.m.**

97

98 Hearing nothing further on investigations, Chair Holm entertained review of public comments. As
99 indicated at the board's previous meeting, no oral public comments on the proposed SB 74
100 regulations, PDMP fees, and various changes to licensure requirements, collaborative practice,
101 refills, wholesale distributor licensing, and disciplinary actions were going to be heard at this time.
102 Before reviewing written public comments submitted to the regulations specialist and in the
103 interest of time, Chair Holm called for Caren Robinson to present on behalf of the Alaska
104 Pharmacist Association.

105

106 *(Suspend review and discussion of public comment at 9:55 a.m.)*

107 *(Resume review and discussion of public comment at 10:16 a.m.)*

108

109 **Agenda Item 12 Pharmacy Industry Update Time: 9:55 a.m.**

110

111 Alaska Pharmacists Association

112 Addressing the pharmacy industry update, Caren Robinson with the Alaska Pharmacists
113 Association presented to the board a summary of the bills supported by the association as well as
114 an update on pharmacy school student activities. Ms. Robinson informed the board that ten (10)
115 pharmacy school students will be attending the senior center to do vaccinations and will be here
116 on Friday to shadow the board's meeting on Friday, March 2nd. Ms. Robinson reviewed Senate Bill
117 32 (the bill addressing biologics), HB 240 (fair audit bill), and Senate Bill 37, which the board will
118 discuss under Agenda Item #17, Legislative Update.

119

120 **Agenda Item 6 Public Comment Time: 10:16 a.m.**

121

122 The board had three separate regulations projects out for public comment and were ready to
123 review them. Donna Bellino clarified that the regulation project that closed for public comment
124 on February 26, 2018 was not yet ready for review as some of the comments arrived via snail mail
125 and couldn't be included in the board packet in time.

126

127

128

129 PDMP Fee Regulations (Closed February 21, 2018)

130 The board first reviewed public comments relating to the proposed PDMP fee under centralized
131 regulation, 12 AAC 02.107, which would establish an initial registration fee of \$50.00 as well as a
132 \$50.00 renewal fee to be paid every two years. Lana Bell commented that she has received
133 feedback from several licensees opposing this proposal, to which Chair Holm agreed but indicated
134 that when the bill on this was being heard, licensees didn't come forward to testify against it. Chair
135 Holm added that because the authority for establishing fees for the database is now written in
136 statute, the board doesn't have the ability to retract the proposed fee or to not require such. Lana
137 Bell inquired as to whether the fee could be lowered, to which Ms. Carrillo responded that the
138 division would be reviewing all 245 public comments before making any final determination on
139 the proposed fees. Chair Holm prompted Ms. Carrillo for clarification as to whether the board is
140 required to take action on the public comments, to which Ms. Carrillo indicated this was not
141 required as the proposed change is to a centralized regulation rather than to the board's
142 regulations under 12 AAC 52. Tammy Lindemuth inquired as to what the reason is for now
143 charging a fee when the database has been in place since 2008, to which Chair Holm and Rich
144 Holt stated that the database is entirely grant funded and will need to be sustained by fees. Chair
145 Holm added that it's possible the fee could be adjusted to only cover the costs that are necessary
146 regardless of whether there's an available grant to cover some of the costs. The board expressed
147 interest in hearing what other states require a registration fee or renewal fee.

148

149 **TASK**

150 Laura Carrillo will post a notice to the board's website stating that the board has reviewed the
151 public comments relating to the PDMP fees, but that the board cannot take action on the
152 comments due to the fee language being under centralized regulations rather than the board's
153 regulations. The board requests that further language be added to clarify that the division will
154 review all comments before the fee is implemented.

155

156 **TASK**

157 Laura Carrillo will send out a poll asking what states require a registration fee.

158

159 Senate Bill 74 Regulations (Pertaining to PDMP access; closed February 15, 2018)

160 The board then moved on to reviewing written public comments on the SB 74 regulations
161 pertaining to PDMP requirements, including changes to:

162

- 163 • 12 AAC 52. 855 – Registration requirements with the PDMP
- 164 • 12 AAC 52. 860 – Access and conditions for use
- 165 • 12 AAC 52. 865 – Reporting and reviewing requirements
- 166 • 12 AAC 52. 870 – Waiver of electronic submission of data
- 167 • 12 AAC 52. 880 – Correct statute citation referencing Medicaid reform
- 168 • 12 AAC 52. 885 – Purge of database records
- 169 • 12 AAC 52. 890 – Grounds for discipline and reporting of PDMP violations
- 170 • 12 AAC 52. 920 – Disciplinary guidelines for PDMP violations

- 171 • 12 AAC 52. 995 - Definition of practitioner relating to PDMP

172

173 Chair Holm called for break at 10:50 a.m.

174

175 *Off record at 10:50 a.m.*

176 *On record at 11:02 a.m.*

177

178 Returning for break, the board honed in on a comment submitted by Health and Social Services,
179 Deputy Commissioner, Jon Sherwood who wanted to bring to the board's attention a
180 recommended citation to use in lieu of the citation in the current proposed language in 12 AAC
181 52.855(e). Ms. Carrillo commented that the statute in the current proposed change makes
182 reference to AS 47.07.038, which is actually no longer in effect; Jon Sherwood recommended
183 instead to cite AS 47.05.270. Chair Holm requested additional information on the latter statute as
184 it is unclear as to how the statute relates specifically to the PDMP.

185

186 The board then addressed confusion of the time computation, however, it was clarified that this is
187 already clearly articulated under 12 AAC 02.920(b).

188

189 **TASK**

190 Ms. Carrillo will ask for further clarification for DHSS on the relevance of AS 47.05.270 to the
191 PDMP.

192

193 **Agenda Item 8** **Budget Report/Division Update** **Time: 11:38 a.m.**

194

195 *Melissa Dumas joined the room at 11:38 a.m.*

196 *Melissa Dumas left the room at 11:42 a.m.*

197

198 Melissa Dumas, Administrative Officer, joined the room to provide the board's budget report for
199 the FY18 2nd quarter. Ms. Dumas reminded the board that they're currently in a renewal year and
200 are incurring revenue. It was added that the board has incurred \$86,000 this year but will likely
201 bring in \$800,000 for the total year. Ms. Dumas also informed the board that their total personal
202 services so far is \$107,837, that their travel expenses is at \$3,664, and that there is no anticipated
203 fee increase for the board at this time.

204

205 **Agenda Item 9** **Board Business** **Time: 11:44 a.m.**

206

207 *Marilyn Zimmerman joined the room at 11:44 a.m.*

208 *Marilyn Zimmerman left the room at 12:16 a.m.*

209

210 Review Applications

211 After a concise and informative budget report, the board moved onto board business, beginning
212 with the review of applications. Due to the nature of the discussions relating to tabled applications
213 and default revocations, the board entertained a motion to enter executive session.

214 On a motion duly made by Anne Gruening in accordance with AS 44.62.310(c)(2), the
215 board unanimously moved to enter executive session for the purpose of discussing
216 subjects that tend to prejudice the reputation and character of any person, provided the
217 person may request a public discussion.

218
219 Staff members, Donna Bellino, Laura Carrillo, and Marilyn Zimmerman were authorized
220 to remain in the room.

221
222 *Off record for executive session at 11:46 a.m.*

223 *On record for public discussion at 11:58 a.m.*

224
225 Upon return from executive session, Chair Holm clarified for the record that no motions were
226 made during executive session, but indicated that the board was ready to take action on tabled
227 applications and matters involving default revocations and a voluntary surrender

228
229 On a motion duly made by Anne Gruening to approve the pharmacy technician
230 application for Ric Allen in consideration of AS 08.80.261(4), seconded by Phil Sanders,
231 and opposed unanimously, it was:

232
233 **RESOLVED to deny the pharmacy technician application for Ric Allen.**

234

	APPROVE	DENY	ABSTAIN	ABSENT
235				
236	Leif Holm	x		
237	Richard Holt	x		
238	Phil Sanders	x		
239	James Henderson	x		
240	Anne Gruening	x		
241	Lana Bell	x		
242	Tammy Lindemuth	x		

243
244 No further discussion.

245
246 On a motion duly made by Anne Gruening to accept the default revocations for Candice
247 Aguilar, Sheila Epling, Jamie Bell, Terry Morris, and Karlee Sturdevant, seconded by Phil
248 Sanders, and approved unanimously, it was:

249
250 **RESOLVED to accept the default revocations for Candice Aguilar, Sheila Epling,**
251 **Jamie Bell, Terry Morris, and Karlee Sturdevant.**

252
253
254
255

	APPROVE	DENY	ABSTAIN	ABSENT
256				
257	Leif Holm	x		
258	Richard Holt	x		
259	Phil Sanders	x		
260	James Henderson	x		
261	Anne Gruening	x		
262	Lana Bell	x		
263	Tammy Lindemuth	x		

264
265 No further discussion.
266

267 **On a motion duly made by Rich Holt to accept the voluntary surrender of Tarnisha**
268 **Bedward-Davis, seconded by Tammy Lindemuth, and approved unanimously, it was:**
269

270 **RESOLVED to accept the voluntary surrender of Tarnisha Bedward-Davis.**
271

	APPROVE	DENY	ABSTAIN	ABSENT
272				
273	Leif Holm	x		
274	Richard Holt	x		
275	Phil Sanders	x		
276	James Henderson	x		
277	Anne Gruening	x		
278	Lana Bell	x		
279	Tammy Lindemuth	x		

280
281 No discussion.
282

283 **TASK**

284 Ms. Carrillo will be sure to add the applications for Rex Malcom and Jennifer La Tourelle for
285 discussion at the board’s next meeting.
286

287 Review Reports of Lost or Stolen Rx:

288 Hearing nothing further on disciplinary actions, default revocations, or voluntary surrenders, the
289 board moved to reviewing reports of lost or stolen prescriptions. Included in the board’s packet
290 were reports submitted by the Alaska Managed Care Pharmacy #1829, Carrs Pharmacy #1812 and
291 CVS Pharmacy #1704. Ms. Carrillo inquired to the board what the typical protocol is for
292 reviewing these reports, and whether the board usually takes action based upon what is reported.
293 Chair Holm clarified that these reports are only reviewed, but that action may be taken if there are
294 outstanding concerns that warrant further investigation.
295

296 Review and Approval of Outstanding Continuing Education Audits
 297 The board then moved on to discussion of continuing education audits from the June 30, 2016
 298 renewal period. Donna Bellino informed the board that the certificates of completion have already
 299 been screened during a preliminary administrative review.
 300

301 **On a motion duly made by Rich Holt to accept the continuing education certificates for**
 302 **individuals with outstanding audits, seconded by James Henderson, and approved**
 303 **unanimously, it was:**
 304

305 **RESOLVED to close the 2016 continuing education audits for Melanie Kluck,**
 306 **Heidi Brainerd, Giyae Lee-Thompson, Sean Berkey, Constance Reyes, Vincent Greear,**
 307 **Margaret Saam, Leanne Stephenson, Mary Bowen, David Thompson, Robert Grogan,**
 308 **Eric LeBoeuf, Lisa Gore, Mike Branson, Ronald Simono, John Davis, Sonja Marie Foutty,**
 309 **Katherine Farrington, Lester Kish, Marlene Perschbacher, Elaine Grant, Amy Rowan,**
 310 **Sonia Ceng, Jane Russell, Lorinda Girourard, Cynthia McCoy, Rodney Gordon, Barbara**
 311 **Antal, Brant Herman, David Atahey, Jamie Lynn Malstrom, Justin May, Emily Thomas,**
 312 **Chhayal Dalal Thomas, Wilbur Graves, Randal Brown, Jared Rawlings, Gary Scott, Jeffrey**
 313 **Gaarder, Alexander Kappleman, Ronald Houle, Gale Rae Berkey, Susan Wheeler, Ben**
 314 **Jensen, Sean Berkey, Denise Every, Kali Allen, Deborah Padilla, Elizabeth Leraas, Nancy**
 315 **Schaefer, Carrie Lang, Laura Olienyk, Deon Pretorius, Jeffrey Stevens, Forrest Fentress,**
 316 **Piper Machamer, Emily Phipps, Mark Johnson, Jill Reid, Killsoo Jang, Adam Vorke, Erin**
 317 **Bollinger, Robyn Goff, Ryan Hardcastle, Lisa Babiak, Tolulope Balogun, Donat Doni,**
 318 **Ashley Kobylinski, Donald Schumacher, Jeffrey Unger, Dominique Lauten, Esinaldo**
 319 **Franco-Ferrer, Howard Ganser, Robert May, David Denio, Tracey Hysong, Hsiao-Lan**
 320 **Ng, Kim Boehmer, Julie Mannello, Joyce Schramm, Charles Barnett, Bruce Christensen,**
 321 **Katherine Pratt, Paul Gionet, Lori Devito, Douglas Bartko, Richard Green, Carroll**
 322 **Mortenson, Roger Paul Penrod, and Patrice Bohrer.**
 323

	APPROVE	DENY	ABSTAIN	ABSENT
324 Leif Holm	x			
325 Richard Holt	x			
326 Phil Sanders	x			
327 James Henderson	x			
328 Anne Gruening	x			
329 Lana Bell	x			
330 Tammy Lindemuth	x			

332
 333 Discussion: It was noted that audits for Jessica La'Tourelle and Rex Malcom would be addressed at
 334 a later date.
 335

336 **TASK**

337 Staff will send audit closed letters to all pharmacists whose continuing education audits have
338 closed.

339

340

341 **Agenda Item 10**

Recess

Time: 12:48 p.m.

342

343 The board recessed the meeting at 12:48 p.m. and would resume on March 1, 2018.

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

380 State of Alaska
381 Department of Commerce, Community and Economic Development
382 Division of Corporations, Business and Professional Licensing
383

384 Alaska Board of Pharmacy
385

386 DRAFT MINUTES OF THE MEETING
387 February 28 – March 2, 2018
388

389 By authority of AS 08.01.070(2), and in compliance with the provisions of AS 44.62,
390 Article 6, a scheduled meeting of the Board of Pharmacy was held via WebEx and at
391 the State Office Building, Conference Room A in Juneau, Alaska on February 28 –
392 March 2, 2018.
393

394 These are draft minutes that have not yet been approved by the board.
395

396 Agenda Item 11 Call to Order/Roll Call Time: 9:05 a.m.
397

398 The **March 1, 2018** meeting day was called to order by Chair, Leif Holm at 9:05 a.m.
399

400 Board members present, constituting a quorum:
401

402 Leif Holm, PharmD #PHAP1606 – *Chair*
403 Richard Holt, PharmD #PHAP2008, MBA – *Vice Chair*
404 Phil Sanders, RPh #PHAP776
405 James Henderson, RPh #PHAP1683
406 Anne Gruening, Public Member
407 Lana Bell, RPh #PHAP893
408 Tammy Lindemuth, Public Member
409 Sharon Long, Public Member (effective 03/01/2018; via phone)
410

411 Division staff present:
412

413 Donna Bellino, Occupational Licensing Examiner
414 Laura Carrillo, Records & Licensing Supervisor
415 Virginia Geary, Occupational Licensing Examiner, Board of Veterinary Examiners
416 Gail Bernth, Executive Administrator, Board of Nursing (via phone)
417 Debora Stovern, Executive Administrator, Medical Board (via phone)
418 Sher Zinn, Records & Licensing Supervisor
419

420 Public members present:
421

422 Greg Estep, #PHAP2259, Walgreens (via phone)
 423 Jacob Cooper, Client Relations Manager, Appriss Health
 424 Aimee Bushnell, Office of Senator Hughes
 425 Jeremy Brown
 426 Sara Supe, #PHAP2258
 427 Lis Houchen, NW Regional Director, National Association of Chain Drug Stores
 428 Hal Geiger, Board of Veterinary Examiners, Public Member
 429 Lori DeVito, #PHAP837, Accreditation Commission for Health Care
 430 Marny Rivera, NPC Research, PDMP – DDPI Evaluator
 431 Christine Michetti, #VETV483

432
 433 **Agenda Item 12 Review/Approve Agenda Time: 9:06 a.m.**

434
 435 Chair Holm addressed the agenda for March 1st and commented that the board should re-address
 436 their position on Senate Bill 32 relating to equivalent generic drugs and interchangeable biological
 437 products, which the board had previously opposed. Chair Holm entertained a motion to add this
 438 topic to Agenda Item #13, Pharmacy Industry Updates.

439
 440 **On a motion duly made by Leif Holm to add the topic of reassessing the board’s position**
 441 **on Senate Bill 32 relating to biologics, seconded by Lana Bell, and approved unanimously,**
 442 **it was:**

443
 444 **RESOLVED to approve the March 1, 2018 agenda as amended.**

	APPROVE	DENY	ABSTAIN	ABSENT
447 Leif Holm	x			
448 Richard Holt	x			
449 Phil Sanders	x			
450 James Henderson	x			
451 Anne Gruening	x			
452 Lana Bell	x			
453 Tammy Lindemuth	x			
454 Sharon Long	x			

455
 456
 457 No discussion.

458
 459 **Agenda Item 13 Pharmacy Industry Updates Time: 9:10 a.m.**

460
 461 *Debora Stovern joined the room telephonically at 9:29 a.m.*
 462 *Gail Bernth joined the room telephonically at 9:34 a.m.*
 463 *Debora Stovern and Gail Bernth left the room at 12:57 p.m.*

464 Hearing nothing further on reviewing the agenda, Chair Holm prompted discussion on updates to
465 the pharmacy industry.

466

467 Discussion of Senate Bill 32

468 Chair Holm commented to the board that about a year ago, the board had written a letter in
469 opposition to SB32, which would allow substitution of biosimilar products at a pharmacy level.
470 Chair Holm added that one of the main points against the bill was the requirement for
471 pharmacists to report to the physician whenever a substitution was made, which seemed to place
472 an onerous responsibility to pharmacists. After discussing with bill sponsors the implications this
473 bill would have, the process in actually seemed relatively more similar. Chair Holm clarified that
474 this would involve submitting a claim electronically through a pharmacy benefit manager (PBM)
475 where it would be adjudicated. This method of reporting would effectively satisfy the pharmacist's
476 reporting requirement because physicians have access to these adjudicated reports. Chair Holm
477 further commented that if this bill passes, individuals would have access to these interchangeable
478 drugs without putting an undue burden on pharmacists for providing alternative medications and
479 reporting them. Based on this, Chair Holm recommended that the board support this bill.

480

481 Phil Sanders inquired what the impact would be on an institutional facility in tracking these
482 substitutions in whether physicians have been informed when an interchangeable product has
483 been provided. Rich Holm commented that as long as the information is submitted through an
484 interoperable electronic medical record system, an electronic prescribing technology, a pharmacy
485 benefits manager, or a pharmacy record, this reporting requirement will suffice. Chair Holm
486 reiterated this, asserting that there would be nothing further that a pharmacist would need to do.

487

488 Lana Bell provided a response from a personal perspective, expressing her opposition to having to
489 substitute one prescription before becoming eligible for the other, which seemed to unfairly be
490 done in favor of insurance companies that may have a coverage preference. Ms. Bell emphasized
491 her position as a private person, stating that her opinion isn't to dissuade the board from
492 supporting this bill. Chair Holm stated that the drug does have to be an interchangeable biosimilar
493 in order for a substitution to qualify, alluding to the idea that the specificity and efficacy profiles of
494 the drugs, thereby eliminating concerns of lower quality medications.

495

496 Rich Holt reiterated language in the bill stating that the prescription may indicate to dispense as
497 written, so if stated otherwise and if the prescriber has full confidence in allowing a substitution,
498 this could be done, so long as the patient has the opportunity to provide consent. Mr. Holt
499 commented that when you start a biologic there could be a chance of experiencing a different
500 reaction, which is the risk one takes with chemical and physiological interactions. The board
501 continued to discuss this bill and the implications it has on pharmacists.

502

503 **On a motion duly made by Leif Holm to write a letter in support of SB 32, seconded by**
504 **Rich Holt, and approved unanimously, it was:**

505

506 **RESOLVED to write a letter in support of SB 32.**

507
508
509
510
511
512
513
514
515
516

	APPROVE	DENY	ABSTAIN	ABSENT
Leif Holm	x			
Richard Holt	x			
Phil Sanders	x			
James Henderson	x			
Anne Gruening	x			
Lana Bell	x			
Tammy Lindemuth	x			
Sharon Long	x			

517
518
519

No discussion.

520
521
522
523
524
525
526
527
528
529
530
531
532
533
534
535
536

Alaska Pharmacist Association Convention (Update from Rich Holt)
Rich Holt provided a summary of his presentation at the Alaska Pharmacist Association Convention that was held on February 10, 2018. Mr. Holt stated that he believed the presentation was well received and that it was overall a positive experience. Chair Holm agreed, adding that it resulted in good feedback from licensees. Ms. Bellino inquired what the feedback was on the technicians, to which Rich stated that he presented this topic last because he knew it was a hot topic; technicians expressed some concerns about liability, and Rich Holt stated to them that this would require a review of regulations to address those concerns. Rich added that he also commented to licensees the importance of participating in opportunities for public comments on regulations. Ms. Carrillo asked for clarification on the background of this issue, to which Rich stated that technicians are concerned that as the board re-evaluates technician regulations and moves to recognizing nationally certified technicians and adds more responsibilities to technicians that pharmacists otherwise may have done, this may inadvertently result in technicians not working due to potential liability issues. Phil Sanders commented that this is the trend in which the pharmacy industry is shifting to, and that Alaska should pursue this to stay on track. Rich Holt again reiterated the importance of engaging in public comment at the time these are solicited rather than providing feedback after the fact.

537
538
539
540
541
542
543
544
545
546
547
548

Controlled Substance Advisory Committee
Lana Bell provided an update from the November 14th CSAC meeting, of which she's a current member along eight other subject-matter experts. Ms. Bell added that the current chair of the committee is the attorney general, and the priority agenda item being addressed at this time is the scheduling of drugs on an emergency basis. Ms. Bell commented that because the dilemma of some drugs not currently controlled or otherwise considered illegal, such as kratom, efforts to take street drugs off the streets are limited because these are neither state nor federally scheduled. It was added that in order to pursue emergency scheduling for regulating these drugs, it would require a legislative process. Ms. Bell's thought was that the authority for emergency scheduling of drugs might fall under the Board of Pharmacy. Ms. Carrillo commented that the bill doesn't explicitly mention AS 08.80, so resources to schedule these meetings would likely stay under the

549 Department of Law with the attorney general rather than transferring the duties of such
550 scheduling under the purview of the board. Ms. Bell then stated that the committee is tracking the
551 progress of the Office of Substance Misuse of Addiction Prevention (OSMAP), led by Andy
552 Jones, to oversee strategic plan efforts for the opioid issue in relation to criminal justice-involved
553 populations. Ms. Bell also informed the board that the CSAC is working with the Department of
554 Corrections to develop treatment plans for inmates with a history of drug abuse with the ultimate
555 goal of reducing the likelihood of recidivism and relapse upon release. With all these efforts, Ms.
556 Bell added that OSMAP would be working to develop relevant stakeholders involved in these
557 initiatives.

558 559 NABP Annual Meeting

560 The Board discussed the NABP annual meeting that will be held on from May 5 – 8, 2018 in
561 Colorado. Chair Holm inquired as to whether the NABP would cover this cost, to which Ms.
562 Bellino affirmed. Chair Holm and Phil Sanders indicated their interest in possibly attending. Lana
563 expressed her positive experience in previously attending the meeting, and Donna Bellino
564 indicated that a travel grant is available for an attendee from our state.

565 566 **TASK**

567 Leif Holm and Phil Sanders will provide staff with an update by mid-March as to whether they
568 would be attending the NABP annual meeting.

569 570 Poison Prevention Packaging Act (PPPA), Investigations, and Inspections

571 The board reviewed documents relating to the PPPA provided by David Burns from the U.S.
572 Consumer Protection act and how it relates to inspections. What David Burns is proposing is to
573 reimburse the board for conducting inspections, however, the board may only be compelled to
574 engage in an inspection if the issue relates to a federal law regarding the practice of pharmacy.
575 After further review, Chair Holm noted that the document indicates the reimbursement inspection
576 services would be only for in-state independent pharmacies and would not apply to an out-of-state
577 pharmacy, and that the focus of the inspection would be on child-resistant packaging. Lana Bell
578 commented that focusing only on this aspect of an inspection wouldn't be an efficient investment
579 of the board's time. After the board discussed this opportunity, it was determined that there is no
580 current need for this service. Chair Holm stated that the need is for assistance with in-state
581 inspections, not for out-of-state inspections who are already required to submit inspection reports
582 from their

583
584 The board also discussed the differences between investigations and inspections. It was clarified
585 for Ms. Carrillo that the two are separate, but that latter is not regularly done even though the
586 board has the authority to provide inspections under AS 08.80.030(b)(3) with inspectors defined
587 under 12 AAC 52.995. Inspections have been geographically limited to the Anchorage area
588 because of the lack of resources to send inspectors to other parts of the state.

589 590 **TASK**

591 Laura Carrillo will follow-up with David Burns on the board's discussion of the PPPA and
592 reimbursement proposal.

593

594 Off record at 10:14 a.m.

595 On record at 10:25 a.m.

596

597 Prescription Drug Monitoring Program

598 Laura Carrillo provided an update on the PDMP by first providing a summary of new registration,
599 prescription, and dispensation data. Ms. Carrillo then gave the board a summary of her PDMP
600 presentation from the Connecting with Data 2018 Pre-Summit Conference in Anchorage on
601 January 15th. Ms. Carrillo informed the board that the presentation included a summary of PDMP
602 goals, a timeline of database implementation, interaction requirements, database enhancements
603 such as prescriber report cards, and challenges such as identifying individuals who are required to
604 register. Chair Holm inquired as to whether we know if we're at 100% registration, or in other
605 words if we know whether all licensees required to register are in fact registered, to which Ms.
606 Carrillo stated currently, the PDMP doesn't have a license integration feature and that CBPL
607 doesn't track DEA registrations. This makes it difficult to capture all the currently active licensees
608 who also hold an active DEA registration, which is the criteria used to determine whether a
609 practitioner is required to register with the database. Jacob Cooper added that Appriss Health
610 works with 42 other states and tracking who and who isn't required to register or review patient
611 prescription history is a ubiquitous challenge, but this is an aspect that the board can improve on
612 with the assistance of Appriss. Another concern was the issue of purging records, which Chair
613 Holm stated was a finding made during the board's last legislative audit. Jacob Cooper stated the
614 purging of records can be arranged based upon Alaska's needs and obligations. With regards to
615 prescriber reports, Ms. Carrillo stated that secondary specialties are used as a comparison measure
616 on prescriber reports and Jacob Cooper commented that Appriss is currently exploring a way to
617 compare prescribing practices on the tertiary specialty level. Chair Holm then expressed concern
618 about purging of records, which was noted as a deficit on the board's last legislative audit. Jacob
619 affirmed that the board could work with Appriss Health to set up a purging mechanism.

620

621 Hal Geiger, public member with the Board of Veterinary Examiners commented that veterinarians
622 face unique challenges because of their patient base and identifying them. Mr. Geiger inquired
623 whether it was known how many veterinarians are registered and whether they're complying, to
624 which Ms. Carrillo stated that approximately 80% of licensed veterinarians are registered, but that
625 knowing whether they're compliant would require an audit. Christine Michetti, veterinarian, stated
626 that the specific challenge in identifying patients is the birthdate and name. The board discussed
627 this concern and the unique challenges the veterinarian board faces. Jacob Cooper added that
628 AWARe has a power algorithm to determine whether one pet is the same pet as another, and
629 providers can also consolidate accounts when aspects of a pet's profile differs slightly, e.g.:
630 misspellings in name or change in birth date. Ultimately, the Board of Veterinarian Examiners can
631 establish regulations for identifying patients. Dr. Michetti expressed concern of veterinarians being
632 disciplined for not catch pet owners who divert drugs. Chair Holm commented that at minimum,
633 practitioners only do their due diligence to review a patient's prescription history, so if a

634 veterinarian isn't able to catch a pet owner who abuses their animal's prescriptions or diverts them,
635 they are still fulfilling their obligation to review the database. Chair Holm added that as long as the
636 veterinarian is registered and reviews as required, they shouldn't be worried of being noncompliant
637 with the PDMP interaction requirements. The board discussed limitations of supply for
638 veterinarians, which Ms. Carrillo stated is limited to a seven-day supply for an initial opioid
639 prescription for animal patient. Dr. Michette stated that veterinarians sometimes prescribe more
640 than a seven-day supply, which Chair Holm stated that this should be charted in clinic notes when
641 a supply exceeds the initial limitation.

642
643 On PDMP data updates, Ms. Carrillo commented that since 2016, registrations have doubled and
644 review of patient prescription history has increased substantially, with the peak coinciding with the
645 date in which mandatory review requirements went into effect in July, 2017. Ms. Carrillo also
646 stated that registrations appear to be going down slightly since the effective date, to which James
647 Henderson inquired as to whether this may be due people leaving the state. Ms. Carrillo
648 acknowledged this, stating that the data isn't population adjusted but is a good aspect to consider.
649 It was further added that some information provided in the PDMP report is also included in and
650 expounded upon within the 2018 legislative report.

651
652 Ms. Carrillo then moved on to forms that would be created as a result of the PDMP receiving its
653 own program in the CBP licensing database, which is the current intent moving forward. Forms
654 would include an initial payment form, renewal payment form, and PDMP change in status form.
655 Ms. Carrillo stated that practitioners choose not to renew their professional license or DEA
656 registration, their access to the PDMP should be inactivated, so the status form would prompt this
657 account change. Similarly, delegates who are no longer employed by a certain provide should also
658 not have access to the PDMP.

659
660 Ms. Carrillo then addressed the legislative report for the board's review and approval, which
661 includes a summary of the database and information on the PDMP vendor and platform, Appriss
662 Health and AWARe, respectively. Additionally, the legislative report includes updates on the
663 board's progress with regards to overseeing registration requirements and completing deliverables
664 as a result of receiving federal grants, including creating an awareness survey and feedback
665 questionnaire as a result of a receiving a Data Driven Prevention Initiative (DDPI) grant from the
666 CDC. Marny Rivera, an evaluator contracted by DHSS was on the line to comment on the need
667 for board member interviews in gauging progress with the PDMP and collaboration with DHSS.
668 The board continued to review the legislative report and ultimately decided that a few topics
669 should be added before the board approves it.

670
671 Rich turned the board's attention to data access, citing AS 17.30.200(j) indicated that the board is
672 to notify any person whose prescription information is improperly accessed. Ms. Carrillo stated
673 that the board has not yet done this and there is not an established standard for notifying patients.
674 The board discussed inadvertent consequences of contacting a patient to inform them of the
675 information that was inappropriately accessed as this could potentially be a confidentiality breach
676 issue, or nonetheless very sensitive. The board requested a legal opinion on this statute.

677

678 **TASK**

679 Laura Carrillo will request a legal opinion on AS 17.30.200(j), specifically what the board is
680 required to do and how this should be carried out.

681

682 **TASK**

683 Laura Carrillo will add information to the legislative report regarding mass mail-outs to
684 unregistered licensees

685

686 **TASK**

687 Leif Holm will contact Marny Rivera to participate in a board member interview for the DDPI
688 grant.

689 Accreditation Commission for Health Care

690 Lori Devito presented to the board information on ACHC's PCAB accreditation, which Ms.
691 Devito clarified is not an inspection—that it actually exceeds qualities of inspections—and that
692 ACHC is not a regulatory agency, but an entity that establishes standards that state regulatory
693 agencies can choose adopt. Ms. Devito added that PCAB accreditation is a program that the
694 commission acquired in 2014, and that results aren't sent to the board but can be if required or
695 recommended by the board. Some states have required PCAB accreditation, such as Michigan, but
696 ACHC ultimately encourages this accreditation as a standard for compounding pharmacies rather
697 than encourages that this standard be put in statute or regulation. Ms. Devito further added that a
698 big focus on ACHC is quality control and that they provide workshops for pharmacists. Ms.
699 Devito summarized the PCABP process and stated the cost is approximately \$8,500, which is
700 incurred by individual pharmacies, not by the state. Chair Holm commented that this is a top
701 notch company, and encouraged the board to support ACHC PCAB as a compounding pharmacy
702 standard. Rich Holt commented that inspections from out-of-state pharmacies are only required to
703 submit inspections from their home jurisdiction that was completed within the two years
704 preceding their application, alluding to the need to clarify whether this standard could be
705 implemented even for out-of-state pharmacies.

706

707 Chair Holm called for break.

708

709 *Off record at 12:05 p.m.*

710 *On record at 12:13 p.m.*

711

712 Appriss Health

713 Jacob Cooper introduced himself as the client relations manager for Alaska, informing the board
714 that Appriss started in Alaska back in 1999 with a victim notification program partnership with the
715 Alaska Department of Corrections. Chair Holm inquired about this program, and Jacob Cooper
716 stated that this is the first program in which Appriss began working with sensitive data; the victim
717 notification program sends updates to victims when their perpetrator is released from jail, goes on
718 probation, or are otherwise recorded by the criminal justice system as having a new action. Jacob
719 cooper then moved on to the PDMP program in Alaska, including updates on PMP InterConnect,

763 **Agenda Item 14** **Recess**

Time: 12:57 p.m.

764
765
766
767
768
769
770
771
772
773
774
775
776
777
778
779
780
781
782
783
784
785
786
787
788
789
790
791
792
793
794
795
796
797
798
799
800
801
802
803
804
805

After the PDMP update, Phil Sanders and Chair Holm called for recess at 12:57 p.m.

806 State of Alaska
807 Department of Commerce, Community and Economic Development
808 Division of Corporations, Business and Professional Licensing

809
810 Alaska Board of Pharmacy

811
812 DRAFT MINUTES OF THE MEETING
813 February 28 – March 2, 2018

814
815 By authority of AS 08.01.070(2), and in compliance with the provisions of AS 44.62,
816 Article 6, a scheduled meeting of the Board of Pharmacy was held via WebEx and at
817 the State Office Building, Conference Room A in Juneau, Alaska on February 28 –
818 March 2, 2018.

819
820 These are draft minutes that have not yet been approved by the board.

821
822 Agenda Item 1 Call to Order/Roll Call Time: 8:58 a.m.

823
824 The **March 2, 2018** meeting day was called to order by Chair, Leif Holm at 8:58 a.m.

825
826 Board members present, constituting a quorum:

827
828 Leif Holm, PharmD #PHAP1606 – *Chair*
829 Richard Holt, PharmD #PHAP2008, MBA – *Vice Chair*
830 Phil Sanders, RPh #PHAP776
831 James Henderson, RPh #PHAP1683
832 Anne Gruening, Public Member
833 Lana Bell, RPh #PHAP893
834 Tammy Lindemuth, Public Member
835 Sharon Long, Public Member (effective 03/01/2018; via phone)

836
837 Division staff present:

838
839 Donna Bellino, Occupational Licensing Examiner
840 Laura Carrillo, Records & Licensing Supervisor
841 Jun Maiquis, Regulations Specialist

842
843 Public members present:

844
845 Greg Estep, #PHAP2259, Walgreens (via phone)
846 Dirk White

848 **Agenda Item 14** Review/Approve Agenda

Time: 9:06 a.m.

849
850 Chair Holm addressed the agenda for March 2nd and commented that the board should establish
851 the board’s new secretary.

852
853 **On a motion duly made by Lana Bell to add voting of a board secretary to the agenda,**
854 **seconded by Rich Holt, and approved unanimously, it was:**

855 **RESOLVED to approve the March 2, 2018 agenda as amended.**
856
857
858

	APPROVE	DENY	ABSTAIN	ABSENT
859 Leif Holm	x			
860 Richard Holt	x			
861 Phil Sanders	x			
862 James Henderson	x			
863 Anne Gruening	x			
864 Lana Bell	x			
865 Tammy Lindemuth	x			
866 Sharon Long	x			

867
868
869 No discussion.

870
871 **Agenda Item 15** Board Business

Time: 9:06 a.m.

872
873 *Dirk White joined the room at 9:28 a.m.*
874 *Dirk White left the room at 10:12 a.m.*

875
876 *Anne Gruening joined the room at 10:00 a.m.*
877 *Anne Gruening left the room at 10:23 a.m.*

878
879 Board Positions

880 The board moved to voting on a board secretary.

881
882 **On a motion duly made by Lana Bell to vote Tammy Lindemuth as the board secretary,**
883 **seconded by Rich Holt, and approved unanimously, it was:**

884
885 **RESOLVED to elect Tammy Lindemuth as the board secretary effective 03/02/2018.**
886

	APPROVE	DENY	ABSTAIN	ABSENT
887 Leif Holm	x			

889	Richard Holt	x
890	Phil Sanders	x
891	James Henderson	x
892	Anne Gruening	x
893	Lana Bell	x
894	Tammy Lindemuth	x
895	Sharon Long	x

896

897 No discussion.

898

899 Legislative Report

900 Sharon Long inquired as to whether the board would be reviewing and approving the legislative
 901 report that was drafted by Ms. Carrillo, to which Chair Holm commented that in the interest of
 902 time, the board would be reviewing and approving via an email ballot.

903

904 Board Contacts

905 Leif Holm and Rich Holt will continue to serve as legislative contacts on behalf of the board.

906

907 Review Legislation

908 Chair Holm then prompted the board to discuss the various pieces of legislation that the board is
 909 affected by, as well as legislation that the board is tracking as FYI bills.

910

- 911 • HB9/SB37: Pharma BD & Employees; Drug Dist/Manu
 - 912 ○ Licensing of out of state wholesale distributors and providing for an executive
 - 913 administrators
 - 914 ○ Already passed the Senate, needs hearing in House Finance
 - 915 ○ Would require substantial regulations
- 916 • HB43: New Drugs for the Terminally Ill
 - 917 ○ Passed House unanimously
 - 918 ○ FYI
- 919 • HB90: Occ. Licensing Fees; Investigation Costs
 - 920 ○ Withdrawn effective 02/23/2018
- 921 • HB262: Military Spouse Courtesy License
 - 922 ○ DCCED would have to report licenses to join committee each year
 - 923 ○ Submit report to legislature
 - 924 ○ Must provide a temporary license
- 925 • SB32: Prescriptions for Biological Products
 - 926 ○ Board changed position in support of bill
 - 927 ○ Would require regulations
- 928 • SB79: Opioids; Prescriptions; Database; Licenses
 - 929 ○ Removes, “cannot be shared with federal government”

- 930 ○ Similar to HB 159 language
- 931 ● SB112: Workers Compensation; Drug Database
 - 932 ○ Intent is to get folks back to work and reduce dependency on opioids
 - 933 ○ Is a priority of the Alaska Chamber of Commerce
 - 934 ○ Reduce unproductive litigation; attempts to shift time and money from workers comp
 - 935 board and onto effective and impartial administrative procedures
- 936 ● SB146: AG Schedule Controlled Substances
 - 937 ○ Changes chair of CSAC from attorney general to president of Board of Pharmacy or
 - 938 president's delegate
 - 939 ○ Participate in emergency scheduling of drugs
- 940 ● HB326/SB120: Naturopaths; Licensing; Practice
 - 941 ○ Would give prescriptive authority to naturopaths
 - 942 ○ FYI
- 943 ● SB209: Prescription Drug Pricing
 - 944 ○ Scheduled for hearing on March 7th, 2018
 - 945 ○ Already in practice that pharmacists disclose and document price for out-of-pocket and
 - 946 retail

947
948 *Off record at 10:13 a.m.*

949 *On record at 10:27 a.m.*

950

951 **Agenda Item 6 Public Comment**

Time: 10:27 a.m.

952

953 *Jun Maiquis entered the room at 10:58 a.m.*

954 *Jun Maiquis left the room at 11:03 a.m.*

955

956 The board returned to reviewing public comments, which was first addressed on day 1 of the
957 meeting. Having already reviewed public comments relating to PDMP use and access. As well as
958 comments relating to the PDMP fees, Chair Holm prompted the board to address the public
959 comments that ended on February 26, 2018, including:

960

- 961 ● 12 AAC 52.120 - Review of pharmacist intern license application, is proposed to be changed to
- 962 amend the checklist requirements for pharmacist intern license application.
- 963 ● 12 AAC 52.130 - Registration of pharmacies located outside of the state, is proposed to be
- 964 changed to clarify the provisions related to applications for registration of pharmacies located
- 965 outside of this state.
- 966 ● 12 AAC 52.200 - Pharmacist-in-charge, is proposed to be changed to amend the requirements
- 967 for a pharmacist designated to replace the pharmacist-in-charge of a pharmacy.
- 968 ● 12 AAC 52.240 - Pharmacist collaborative practice authority, is proposed to be changed to
- 969 amend the pharmacist collaborative practice authority requirements.
- 970 ● 12 AAC 52.470 - Refills, is proposed to be changed to amend the provisions related to
- 971 ● prescription drug order refills.

- 972 • 12 AAC 52.510 - Substitution, is proposed to be changed to clarify the provisions related to
973 notes or wording on the prescription drug order.
- 974 • 12 AAC 52.610 - Wholesale drug distributor license, is proposed to be changed to amend the
975 provisions related to a change in facility manager.
- 976 • 12 AAC 52.991 - Disciplinary decision or conviction reporting requirement, is proposed to be
977 changed to add the requirement that a licensed or registered facility report in writing to the
978 board any disciplinary decision or conviction
979

980 James Henderson addressed the proposed changes 12 AAC 52.470 pertaining to refills, inquiring
981 what the rational for the 30 days was, to which Chair Holm stated that the intent was to see
982 whether a patient does well with this day supply before providing for a longer supply. Phil Sanders
983 pointed to a study included along with one of the comments, stating that patients with 90-day
984 refills had greater medication adherence, greater persistency, normal wastage, and greater savings.
985 Rich indicated that it is a restriction, so it might be reasonable to expand to 90 days. The board
986 deliberated on whether to extend to 90 days or to 100 days.
987

988 The board then discussed proposed changes to 12 AAC 52.120, which would require a pharmacy
989 intern to submit a certificate of moral character from two reputable citizens. Some comments on
990 this proposed regulation included concern that this requirement would add to the already delayed
991 processing of inter applications. Ms. Bellino commented that with the addition of the
992 jurisprudence questionnaire, the processing time can now be more efficient as this eliminates
993 waiting time; prior to the board’s resolution at the November - December 2017 meeting to include
994 the jurisprudence questionnaire, the questionnaire was to applicants after their documents were
995 received. Lana Bell stated that currently, intern licenses aren’t issued until one month before their
996 rotation is supposed to start, to which Ms. Bellino stated this is the timeline that has always been
997 in place. Ms. Carrillo inquired as to whether this requirement is in regulation or an established
998 preference by the board. Rich Holt and Ms. Bellino stated that this has been the typical process,
999 but Ms. Carrillo suggested that the licenses be issued upon completion rather than waiting until a
1000 month before a rotation begins. Chair Holm prompted the discussion to focus back on the public
1001 comment concern of processing time. Ms. Bellino stated that the certificates of moral character
1002 could be included in the application itself, so it wouldn’t really add to the processing delay.
1003

1004 **TASK**

1005 Ms. Carrillo will discuss with the other Records & Licensing Supervisor who supervises
1006 pharmacist interns and technicians the idea of issuing intern licenses upon application completion
1007 rather than one month prior to the intern’s rotation.
1008

1009 After reviewing public comments to the proposed regulations, Chair Holm called for motions.
1010

1011 **On a motion duly made by Rich Holt that in light of public comment, to accept**
1012 **regulations 12 AAC 52.120 (pharmacy intern application), 12 AAC 52.130 (review of**
1013 **applications of pharmacies located outside of the state), 12 AAC 52.200 (pharmacists-in-**
1014 **charge), 12 AAC 52.240 (pharmacists collaborative practice authority), 12 AAC 52.510**

1015 (substitution), 12 AAC 52.610 (wholesale drug distributor), 12 AAC 52.991 (disciplinary
 1016 decision or conviction reporting); amend 12 AAC 52.470(d) to state: “If an original
 1017 prescription drug order is prescribed as a 30-day supply, the pharmacist may dispense up
 1018 to a 100-day supply on refills provided that the”; strike 90-day to 100-day, strike (1) patient
 1019 has completed and initial 30-day supply of the drug”. Seconded by Tammy Lindemuth,
 1020 and approved unanimously, it was:

1021
 1022 **RESOLVED** to accept proposed regulations 12 AAC 52.120, 12 AAC 52.130, 12 AAC
 1023 52.200, 12 AAC 52.240, 12 AAC 52.510, 12 AAC 52.610, and 12 AAC 52.991 as written, and to
 1024 accept 12 AAC 52.470(d) as amended.
 1025

	APPROVE	DENY	ABSTAIN	ABSENT
1026 Leif Holm	x			
1027 Richard Holt	x			
1028 Phil Sanders	x			
1029 James Henderson	x			
1030 Anne Gruening	x			
1031 Lana Bell	x			
1032 Tammy Lindemuth	x			
1033 Sharon Long	x			

1035
 1036 No further discussion.
 1037

1038 **On a motion duly made by Rich Holt that in light of public comment to accept 12 AAC**
 1039 **52.855 with amending section (e) to read “a pharmacist or practitioner required to register**
 1040 **with the PDMP may access information in the PDMP using another registrants**
 1041 **credentials only as authorized by a contract executed by the department for the purposes**
 1042 **of” and replace existing statute AS 47.07.038 to read AS 47.05.270, and to accept 12 AAC**
 1043 **52.860, 12 AAC 52.865, 12 AAC 52.870, 12 AAC 52.880, 12 AAC 52. 885, 12 AAC 52.890, 12**
 1044 **AAC 52.920, and 12 AAC 52.995 as written, seconded by Tammy Lindemuth, and approved**
 1045 **unanimously, it was:**

1046
 1047 **RESOLVED** to accept the proposed change to 12 AAC 52.855(e) as amended and to
 1048 accept 12 AAC 52.860, 12 AAC 52.865, 12 AAC 52.870, 12 AAC 52.880, 12 AAC 52.885, 12
 1049 AAC 52.890, 12 AAC 52.920, and 12 AAC 52.995 as written.
 1050

	APPROVE	DENY	ABSTAIN	ABSENT
1051 Leif Holm	x			
1052 Richard Holt	x			
1053 Phil Sanders	x			
1054 James Henderson	x			

1056	Anne Gruening	x
1057	Lana Bell	x
1058	Tammy Lindemuth	x
1059	Sharon Long	x

1060
1061 No further discussion.

1062
1063 Jun Maiquis entered the room at 10:58 a.m. Leif inquired whether new public comment is needed
1064 if a change is being made based on the comments, to which Jun Maiquis indicated that another
1065 round for public comment as long as the intent of the proposed changes don't change. Mr.
1066 Maiquis affirmed that this is correct, and that the Department of Law will determine whether the
1067 intent changed as a result of amendments made after consideration of public comment.

1068
1069 **TASK**

1070 Ms. Carrillo will forward the board's resolutions to the proposed regulation changes to the
1071 regulations specialist for implementation.

1072
1073 **Agenda Item 9** **Board Business** **Time: 11:44 a.m.**

1074
1075 The board resumed board business.

1076
1077 Annual Report

1078 Rich Holt, Laura Carrillo, and Donna Bellino will collaborate to work on the annual report due
1079 June 1st.

1080
1081 Wall Certificates

1082 Chair Holm signed wall certificates.

1083
1084 Upcoming Travel

1085 The board addressed travel opportunities, including the NABP Annual Meeting that will be held in
1086 May in Colorado. Leif Holm and Phil Sanders reiterated that they would inform the staff whether
1087 they could attend in by mid-March. A conference in Atlanta titled, 'The National Rx Abuse and
1088 Heroin Summit' was also brought to the board's attention, and Lana Bell expressed her interest in
1089 attending on behalf of the board and for her role as a Pharmacy Board designee on the Controlled
1090 Substance Advisory Committee. Chair Holm inquired as to how attendance would be of benefit,
1091 to which Lana stated that some of the topics discussed during CSACs include complex issues that
1092 Ms. Bell would be able to discuss at a more involved level if she had a better understanding of
1093 opioid issues. Ms. Bell believes that attendance at this conference would enable more active
1094 participation and contribution to the committee.

1095
1096 **TASK**

1097 Ms. Carrillo will submit a travel approval request for Lana Bell to attend the National Rx Drug
1098 Abuse and Heroin Summit from April 2 – 5, 2018 in Atlanta, GA

1099

1100 Reschedule May Meeting

1101 Due to time conflicts with board member and Ms. Carrillo’s schedules, the board rescheduled
1102 their next meeting to be held on May 10th all day and May 11th half day.

1103

1104 Correspondence

1105 The board received a piece of correspondence from a physician who expressed concerns about the
1106 DEA registration number being conspicuously displayed on the prescriber report. The board
1107 discussed possibilities of altering the format and available information on the prescriber report,
1108 however, it was noted that this particular concern on this matter has been the only one brought
1109 forward for their attention thus far. In addition, the board acknowledged that DEA numbers are
1110 included on prescriptions, and that including this number is not a violation of HIPAA. Since there
1111 doesn’t appear to be more widespread concern of DEA confidentiality, there didn’t appear to be
1112 sufficient justification for requesting a change order from Appriss Health. The board still
1113 encouraged staff to find out the cost of this, which was alluded to earlier by Jacob Cooper as being
1114 a fairly expensive change.

1115

1116 **TASK**

1117 Ms. Carrillo will inquire about the cost of obscuring DEA registration numbers on the prescriber
1118 report.

1119

1120 In the interest of time, the board entertained a motion to table outstanding topics that were
1121 scheduled for discussion under Old Business.

1122

1123 **On a motion duly made by Leif Holm to table pharmaceutical waste and disposal,
1124 compounding regulations, proof of satisfactory documentation form draft, and the IHS
1125 pharmacist form draft until the next meeting, seconded by Phil Sanders, and approved
1126 unanimously, it was:**

1127

1128 **RESOLVED to table the topics listed under Old Business for discussion at the May
1129 10 – 11, 2018 meeting.**

1130

1131

	APPROVE	DENY	ABSTAIN	ABSENT
1132 Leif Holm	x			
1133 Richard Holt	x			
1134 Phil Sanders	x			
1135 James Henderson	x			
1136 Anne Gruening	x			
1137 Lana Bell	x			
1138 Tammy Lindemuth	x			
1139 Sharon Long	x			
1140				

1141
1142 No further discussion.
1143 **Agenda Item 16 Adjourn** **Time: 11:30 a.m.**
1144
1145 Hearing nothing further, Chair Holm entertained a motion to adjourn.
1146
1147 **On a motion duly made by Tammy Lindemuth to adjourn the meeting, seconded by Lana**
1148 **Bell, and approved unanimously, it was:**
1149
1150 **RESOLVED to adjourn the meeting at 11:30 a.m.**
1151
1152
1153
1154 ***Laura Carrillo 09/05/2018***
1155 _____
1156 Laura Carrillo, Records & Licensing Supervisor
1157
1158 ***Richard Holt***
1159 _____
1160 Rich Holt, Chair